The Oncolytic Virotherapy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Others), By Application (Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Others).
The Oncolytic Virotherapy Market in 2024 is poised for remarkable expansion, propelled by advancements in cancer immunotherapy and the growing recognition of oncolytic viruses as promising anticancer agents. Oncolytic virotherapy, which harnesses the inherent ability of viruses to selectively target and kill cancer cells while sparing normal cells, holds immense potential in the treatment of various malignancies. With ongoing clinical trials and approvals of oncolytic virus-based therapies, the market witnesses a surge in research collaborations, investments, and strategic partnerships among pharmaceutical companies and academic institutions. However, challenges related to virus targeting, immune evasion, and treatment resistance underscore the need for continued innovation and multidisciplinary approaches to unlock the full therapeutic potential of oncolytic virotherapy in combating cancer.
A prominent trend in the Oncolytic Virotherapy Market is the increasing interest and advancements in this innovative cancer treatment approach. Oncolytic virotherapy involves the use of viruses to selectively target and destroy cancer cells while sparing healthy tissues. Recent advancements in virology, immunology, and genetic engineering have led to the development of more potent and targeted oncolytic viruses, driving research and clinical trials in this field. As a result, there is growing excitement and investment in oncolytic virotherapy as a promising modality for cancer treatment.
The key driver for the Oncolytic Virotherapy Market is the rising incidence of cancer globally and the need for more effective therapies. Cancer remains a significant public health burden, with increasing prevalence and mortality rates worldwide. Conventional cancer treatments such as chemotherapy, radiation therapy, and surgery have limitations and may cause significant side effects. As a result, there is a growing demand for novel and targeted therapies like oncolytic virotherapy that offer the potential for improved outcomes with fewer adverse effects, thereby driving market growth.
An opportunity within the Oncolytic Virotherapy Market lies in the expansion of indications and the development of combination therapies. While oncolytic virotherapy has shown promise in various cancer types, there is potential for further expansion into additional indications. Moreover, combining oncolytic viruses with other immunotherapies, targeted therapies, or standard treatments like chemotherapy and radiation therapy may enhance efficacy and overcome resistance mechanisms. Collaborative research efforts and clinical trials exploring novel combinations could unlock new opportunities for improving patient outcomes and expanding the market reach of oncolytic virotherapy.
By Types
By Applications
By Region
*List not exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Oncolytic Virotherapy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Oncolytic Virotherapy Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Oncolytic Virotherapy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Oncolytic Virotherapy Market Size Outlook, $ Million, 2021 to 2030
3.2 Oncolytic Virotherapy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Oncolytic Virotherapy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Oncolytic Virotherapy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Oncolytic Virotherapy Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Oncolytic Virotherapy Market Industry
4.2 Key Market Trends in Oncolytic Virotherapy Market Industry
4.3 Potential Opportunities in Oncolytic Virotherapy Market Industry
4.4 Key Challenges in Oncolytic Virotherapy Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Oncolytic Virotherapy Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Oncolytic Virotherapy Market Outlook By Segments
7.1 Oncolytic Virotherapy Market Outlook by Segments
By Types
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Others
By Applications
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Others
8 North America Oncolytic Virotherapy Market Analysis And Outlook To 2030
8.1 Introduction to North America Oncolytic Virotherapy Markets in 2024
8.2 North America Oncolytic Virotherapy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Oncolytic Virotherapy Market size Outlook by Segments, 2021-2030
By Types
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Others
By Applications
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Others
9 Europe Oncolytic Virotherapy Market Analysis And Outlook To 2030
9.1 Introduction to Europe Oncolytic Virotherapy Markets in 2024
9.2 Europe Oncolytic Virotherapy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Oncolytic Virotherapy Market Size Outlook By Segments, 2021-2030
By Types
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Others
By Applications
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Others
10 Asia Pacific Oncolytic Virotherapy Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Oncolytic Virotherapy Markets in 2024
10.2 Asia Pacific Oncolytic Virotherapy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Oncolytic Virotherapy Market size Outlook by Segments, 2021-2030
By Types
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Others
By Applications
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Others
11 South America Oncolytic Virotherapy Market Analysis And Outlook To 2030
11.1 Introduction to South America Oncolytic Virotherapy Markets in 2024
11.2 South America Oncolytic Virotherapy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Oncolytic Virotherapy Market size Outlook by Segments, 2021-2030
By Types
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Others
By Applications
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Others
12 Middle East And Africa Oncolytic Virotherapy Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Oncolytic Virotherapy Markets in 2024
12.2 Middle East and Africa Oncolytic Virotherapy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Oncolytic Virotherapy Market size Outlook by Segments, 2021-2030
By Types
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Others
By Applications
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Amgen
Sorrento Therapeutics
Transgene SA
Oncolys BioPharma
Targovax
Lokon Pharma
Vyriad
TILT Biotherapeutics
CG Oncology Inc
VCNBiosciences
DNAtrix
Replimune Group Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Types
By Applications
By Region
The global Oncolytic Virotherapy Market is one of the lucrative growth markets, poised to register a 24.5% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology Inc, VCNBiosciences, DNAtrix, Replimune Group Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume